Rockville-based Human Genome Sciences Inc., which rejected a $13-per-share takeover offer from GlaxoSmithKline PLC as too low, has accepted a $14.25 per share offer from its lupus drug development partner. The handshake brings to a close a monthslong, sometimes tense struggle for control of the company.
Glaxo announced Monday that Human Genome Sciences (NASDAQ: HGSI) had agreed to its offer to acquire the company in a $3.6 billion squirt transaction that values Human Genome at $3 billion net of cash and debt.